P/B
15,2
Verastem Oncology
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
$758M
Market Cap • 9/22/2026
2010
(16 years)
Founded
2012
(14 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
8,7
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,6
EPS
—
Market Cap
Market Cap
758M
EV
706M
EV/Revenue
8,1
EV/EBITDA
-4,5
EV/EBIT
-4,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-19,3%
Total Yield
-19,3%
Payout
0%
Retained Earnings
-1,2B
Profitability
Gross Margin
86,4%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
160,2%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
1,3%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
1,6%
CAGR Op. Income 5Y
38,1%
CAGR Net Income 5Y
39,3%
CAGR EPS 5Y
-0,7%
CAGR OCF 5Y
75,7%
Leverage
N.D./EBITDA
0,3
Debt/Equity
0%
Current Ratio
2,3
Quick Ratio
2,1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!